DOSE INTENSE MOPP FOR PATIENTS WITH POOR PROGNOSIS HODGKIN'S DISEASE

该方案被设计用于治疗霍奇金氏病的子集 治疗失败风险最高的患者。 从先前对晚期霍奇金氏病的研究中，我们已经确定 IIIB、IVA(骨髓)和巨大纵隔霍奇金病患者 疾病的应答率和存活率较低。为了提高 MOPP在这组患者中的疗效，剂量-强度 所有药物都已增加，并在化疗后给予GM-CSF 试图改善这些药物预期的严重骨髓毒性作用 药物剂量增加。到目前为止，6名可评估的患者中有5名已经达到 一个完整的回应。这位诱导失败的患者自那以后 接受了异基因骨髓移植，并实现了完全的 回应。所有可评估的患者都是活着的，没有疾病。 时间到了。这种治疗没有观察到意想不到的毒性。

This protocol was designed to treat the subset of Hodgkin's disease patients who are at highest risk for treatment failure. From the previous study of advanced Hodgkin's disease, we have identified patients with Stage IIIB, IVA (marrow) and massive mediastinal Hodgkin's disease as having lower response and survival rates. In order to improve the efficacy of MOPP therapy in this group of patients, dose-intensity of all drugs has been increased and GM-CSF is given following chemotherapy in an attempt to ameliorate the expected severe myelotoxic effects of these increased drug doses. To date, 5 of the 6 evaluable patients have achieved a complete response. The patient who was an induction failure has since undergone an allogeneic bone marrow transplant and achieved a complete response. All evaluable patients are alive and free of disease at this time. No unexpected toxicities have been observed with this treatment.